| Theme | An up-to-date review of the molecular-targeted therapies for inflammatory bowel disease | |
|---|---|---|
| Title | Ustekinumab for the treatment of inflammatory bowel disease | |
| Publish Date | 2021/09 | |
| Author | Katsuyoshi Matsuoka | Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center |
| [ Summary ] | Interleukin (IL)-12 and IL-23 are cytokines secreted by antigen-presenting cells such as dendritic cells and macrophages. Ustekinumab is a monoclonal antibody directed against IL-12/23 p40, the common subunit of IL-12 and IL-23 and is shown to be effective for induction and maintenance of remission in patients with Crohn's disease and ulcerative colitis. Ustekinumab is a fully human antibody and the incidence of anti-drug antibodies is low; therefore, the rates of loss-of-response tend to be low. Although studies have reported a favorable shortterm safety profile, the long-term safety of this drug warrants future investigation. | |